2017 American Transplant Congress
Correlation of Complement Activating Donor Specific Antibodies as Measured by C3d and Cross-Match Status.
Introduction. Complement dependent cytotoxicity, first described in 1969 is the only functional assay studying complement activation. C3d assay is developed recently to study complement activation…2017 American Transplant Congress
Predicting Immunologic Risk for Acute Rejection in Pediatric Liver Transplantation.
Yale University, New Haven, CT
Background: Studies in heart, lung, kidney, & liver transplantation (LT) indicate an increased negative impact of antibodies (Ab) to HLA on allograft outcome.Aim: To describe…2017 American Transplant Congress
Can Pre-Treatment CDC Titres Predict Graft Outcomes in HLA Incompatible Transplants?
Introduction: Complement Dependent Cytotoxic (CDC) (non-augmented) cross matching and Flow cytometric (FC) cross matching are two commonly used techniques to identify anti- Human Leucocyte Antigen…2017 American Transplant Congress
HLA Class II Molecules Partner with TLR4 to Stimulate Endothelial Cell Activation and Proliferation.
Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA
Background: Transplant recipients developing donor specific HLA antibodies (DSA) are at a higher risk for acute and chronic antibody-mediated rejection (AMR). DSA contribute to the…2017 American Transplant Congress
Anti-HLA I Antibody Enhances Endothelial Cell-Induced Polarization of Human Monocytes to M2a/c-Like Macrophages.
HLA antibody (Ab)-mediated rejection (AMR) is often characterized by graft-infiltrating macrophages, which correlate with tissue fibrosis. Recent studies suggest they may mainly represent M2-polarized macrophages.…2017 American Transplant Congress
A Prospective Iterative Trial of Carfizomib-Based Desensitization Trial: Initial Comparative Observations.
1U of Cincinnati, Cincinnati; 2Christ Hospital, Cincinnati
Carfilzomib (CFZ) is a 2nd generation proteasome inhibitor different form bortezomib in that it irreversibly disables 20s and 26s proteasomes.Results from the first 2 phases…2017 American Transplant Congress
Risk Factors and Consequences of De Novo Anti-HLA Donor Specific Antibodies in Kidney Transplant Recipients: The Force Awakens.
Background: Presence of anti-HLA donor specific antibodies (DSAs) has been associated with inferior kidney transplant outcomes. Identification of risk factors for de novo DSAs could…2017 American Transplant Congress
Low Level Early Onset De Novo DSA's May Not Portend Early Graft Dysfunction in Kidney Transplant Recipients.
Nephrology and Hypertension, Stony Brook Medicine, Stony Brook, NY
Background: The occurrence of anti-HLA de novo DSA (dnDSA) has been associated with the histological features of antibody-mediated rejection (ABMR) on kidney biopsy. The significance…2017 American Transplant Congress
Positive Flow Crossmatch After Negative Virtual Crossmatch -A Single Center Experience.
Pathology and Lab Medicine, London Health Sciences Center, London, ON, Canada
Aims: To determine causes of Flow Cytometry crossmatch (FCXM) after a negative virtual crossmatch (VirXM), even with sensitive solid-phase antibody assay and complete HLA typings…2017 American Transplant Congress
Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 47
- Next Page »